VISEN Pharmaceuticals Repurchases 8,600 Shares, Expands Treasury Stock to 58,300 Units

Bulletin Express06-01 18:23

VISEN Pharmaceuticals (02561) disclosed a next-day return reporting the on-market buyback of 8,600 ordinary shares on 1 June 2026 at prices ranging between HKD 21.54 and HKD 22.00, for a total consideration of HKD 0.19 million (volume-weighted average price: HKD 21.80).

Following the transaction, the company’s issued share capital (excluding treasury shares) fell from 113.88 million to 113.87 million shares, representing a marginal 0.008% reduction. Concurrently, VISEN’s treasury stock balance rose from 49,700 to 58,300 shares.

The repurchase formed part of a mandate granted on 27 June 2025 that authorises the company to buy back up to 11.39 million shares. Cumulatively, VISEN has now repurchased 58,300 shares under this authority, equivalent to 0.05% of the issued shares outstanding on the mandate date.

All 8,600 shares acquired on 1 June have been retained as treasury shares; no cancellations have been executed. In accordance with Hong Kong listing rules, VISEN is subject to a moratorium on issuing, selling or transferring treasury shares until 1 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138234893?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138234893","market":"us","top_or_hot":-1,"title":"VISEN Pharmaceuticals Repurchases 8,600 Shares, Expands Treasury Stock to 58,300 Units","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals (02561) disclosed a next-day return reporting the on-market buyback of 8,600 ordinary shares on 1 June 2026 at prices ranging between HKD 21.54 and HKD 22.00, for a total consideration of HKD 0.19 million (volume-weighted average price: HKD 21.80).</p>\n\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) fell from 113.88 million to 113.87 million shares, representing a marginal 0.008% reduction. Concurrently, VISEN’s treasury stock balance rose from 49,700 to 58,300 shares.</p>\n\n<p>The repurchase formed part of a mandate granted on 27 June 2025 that authorises the company to buy back up to 11.39 million shares. Cumulatively, VISEN has now repurchased 58,300 shares under this authority, equivalent to 0.05% of the issued shares outstanding on the mandate date.</p>\n\n<p>All 8,600 shares acquired on 1 June have been retained as treasury shares; no cancellations have been executed. In accordance with Hong Kong listing rules, VISEN is subject to a moratorium on issuing, selling or transferring treasury shares until 1 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharmaceuticals Repurchases 8,600 Shares, Expands Treasury Stock to 58,300 Units</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharmaceuticals Repurchases 8,600 Shares, Expands Treasury Stock to 58,300 Units\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-01 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals (02561) disclosed a next-day return reporting the on-market buyback of 8,600 ordinary shares on 1 June 2026 at prices ranging between HKD 21.54 and HKD 22.00, for a total consideration of HKD 0.19 million (volume-weighted average price: HKD 21.80).</p>\n\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) fell from 113.88 million to 113.87 million shares, representing a marginal 0.008% reduction. Concurrently, VISEN’s treasury stock balance rose from 49,700 to 58,300 shares.</p>\n\n<p>The repurchase formed part of a mandate granted on 27 June 2025 that authorises the company to buy back up to 11.39 million shares. Cumulatively, VISEN has now repurchased 58,300 shares under this authority, equivalent to 0.05% of the issued shares outstanding on the mandate date.</p>\n\n<p>All 8,600 shares acquired on 1 June have been retained as treasury shares; no cancellations have been executed. In accordance with Hong Kong listing rules, VISEN is subject to a moratorium on issuing, selling or transferring treasury shares until 1 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1138234893","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138234893","pubTimestamp":1780309434,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals (02561) disclosed a next-day return reporting the on-market buyback of 8,600 ordinary shares on 1 June 2026 at prices ranging between HKD 21.54 and HKD 22.00, for a total...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"VISEN Pharmaceuticals回购8,600股，库存股扩大至58,300股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals (02561) disclosed a next-day return reporting the on-market buyback of 8,600 ordinary shares on 1 June 2026 at prices ranging between HKD 21.54 and HKD 22.00, for a total consideration of HKD 0.19 million (volume-weighted average price: HKD 21.80).\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) fell from 113.88 million to 113.87 million shares, representing a marginal 0.008% reduction. Concurrently, VISEN’s treasury stock balance rose from 49,700 to 58,300 shares.\nThe repurchase formed part of a mandate granted on 27 June 2025 that authorises the company to buy back up to 11.39 million shares. Cumulatively, VISEN has now repurchased 58,300 shares under this authority, equivalent to 0.05% of the issued shares outstanding on the mandate date.\nAll 8,600 shares acquired on 1 June have been retained as treasury shares; no cancellations have been executed. In accordance with Hong Kong listing rules, VISEN is subject to a moratorium on issuing, selling or transferring treasury shares until 1 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138234893","isCrawlerRequest":true}